 Samuel Dominguez
Concepts (723)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 27 | 2025 | 175 | 7.540 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 21 | 2026 | 94 | 4.990 |
Why?
| | Respiratory Tract Infections | 24 | 2025 | 399 | 4.890 |
Why?
| | Enterovirus D, Human | 17 | 2025 | 89 | 4.330 |
Why?
| | Multiplex Polymerase Chain Reaction | 12 | 2025 | 56 | 4.240 |
Why?
| | Myelitis | 14 | 2025 | 107 | 3.780 |
Why?
| | Disease Outbreaks | 23 | 2025 | 420 | 3.540 |
Why?
| | Polymerase Chain Reaction | 15 | 2026 | 1046 | 3.170 |
Why?
| | Molecular Diagnostic Techniques | 11 | 2026 | 104 | 3.070 |
Why?
| | Enterovirus | 11 | 2019 | 83 | 2.710 |
Why?
| | Child, Preschool | 85 | 2026 | 12011 | 2.700 |
Why?
| | Meningitis | 8 | 2022 | 80 | 2.600 |
Why?
| | Coronavirus | 10 | 2015 | 47 | 2.590 |
Why?
| | Pleural Effusion | 3 | 2026 | 60 | 2.550 |
Why?
| | Central Nervous System Viral Diseases | 7 | 2025 | 78 | 2.540 |
Why?
| | Infant | 72 | 2026 | 10195 | 2.530 |
Why?
| | Child | 111 | 2026 | 22960 | 2.520 |
Why?
| | Influenza, Human | 13 | 2023 | 634 | 2.420 |
Why?
| | Neuromuscular Diseases | 7 | 2025 | 145 | 2.370 |
Why?
| | Anti-Bacterial Agents | 20 | 2026 | 1940 | 2.310 |
Why?
| | Encephalitis | 11 | 2022 | 142 | 2.170 |
Why?
| | Gastroenteritis | 5 | 2023 | 63 | 2.030 |
Why?
| | Clostridium Infections | 6 | 2024 | 74 | 2.000 |
Why?
| | Anti-Infective Agents | 5 | 2022 | 234 | 1.980 |
Why?
| | Immunoglobulins, Intravenous | 7 | 2026 | 135 | 1.970 |
Why?
| | Colorado | 41 | 2025 | 4591 | 1.800 |
Why?
| | Bacteremia | 4 | 2025 | 222 | 1.750 |
Why?
| | Influenza A Virus, H1N1 Subtype | 7 | 2020 | 161 | 1.740 |
Why?
| | Diarrhea | 7 | 2023 | 193 | 1.620 |
Why?
| | Feces | 9 | 2023 | 500 | 1.620 |
Why?
| | Blood Culture | 2 | 2025 | 27 | 1.550 |
Why?
| | Bacteria | 8 | 2025 | 769 | 1.520 |
Why?
| | Paralysis | 4 | 2018 | 69 | 1.500 |
Why?
| | Hospitals, Pediatric | 13 | 2025 | 571 | 1.490 |
Why?
| | Coronavirus Infections | 9 | 2020 | 378 | 1.440 |
Why?
| | Humans | 175 | 2026 | 147265 | 1.410 |
Why?
| | Infliximab | 5 | 2026 | 111 | 1.400 |
Why?
| | Nervous System Diseases | 5 | 2020 | 288 | 1.390 |
Why?
| | Community-Acquired Infections | 6 | 2026 | 177 | 1.390 |
Why?
| | Bacteriological Techniques | 2 | 2025 | 66 | 1.380 |
Why?
| | Antimicrobial Stewardship | 3 | 2025 | 137 | 1.310 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.290 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2025 | 81 | 1.270 |
Why?
| | Streptococcus pneumoniae | 4 | 2025 | 190 | 1.270 |
Why?
| | Simplexvirus | 3 | 2020 | 82 | 1.260 |
Why?
| | Male | 112 | 2026 | 73928 | 1.230 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 140 | 1.210 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 88 | 1.210 |
Why?
| | Epidemiological Monitoring | 4 | 2025 | 70 | 1.130 |
Why?
| | Sequence Analysis, DNA | 9 | 2026 | 780 | 1.120 |
Why?
| | Streptococcus pyogenes | 3 | 2025 | 41 | 1.120 |
Why?
| | Retrospective Studies | 42 | 2026 | 17561 | 1.080 |
Why?
| | Pandemics | 12 | 2025 | 1719 | 1.080 |
Why?
| | Stevens-Johnson Syndrome | 3 | 2017 | 37 | 1.070 |
Why?
| | Female | 94 | 2026 | 80054 | 1.060 |
Why?
| | Streptococcal Infections | 3 | 2025 | 179 | 1.040 |
Why?
| | Chiroptera | 4 | 2014 | 59 | 1.030 |
Why?
| | Bacterial Infections | 2 | 2020 | 247 | 1.010 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 68 | 1.010 |
Why?
| | Adolescent | 50 | 2025 | 22814 | 1.010 |
Why?
| | Child, Hospitalized | 3 | 2024 | 54 | 1.000 |
Why?
| | Osteomyelitis | 4 | 2026 | 146 | 1.000 |
Why?
| | Nasopharynx | 5 | 2023 | 73 | 1.000 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2021 | 294 | 0.990 |
Why?
| | Spike Glycoprotein, Coronavirus | 8 | 2022 | 129 | 0.980 |
Why?
| | Sensitivity and Specificity | 12 | 2026 | 2017 | 0.980 |
Why?
| | Picornaviridae Infections | 5 | 2019 | 53 | 0.970 |
Why?
| | Specimen Handling | 2 | 2026 | 183 | 0.960 |
Why?
| | Otitis Media | 3 | 2024 | 185 | 0.950 |
Why?
| | Empyema | 1 | 2026 | 8 | 0.930 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2026 | 39 | 0.890 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2025 | 26 | 0.870 |
Why?
| | Respiratory Tract Diseases | 2 | 2024 | 178 | 0.870 |
Why?
| | Communicable Diseases | 2 | 2017 | 166 | 0.850 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 12 | 0.840 |
Why?
| | Infant, Newborn | 20 | 2025 | 6543 | 0.840 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2025 | 58 | 0.830 |
Why?
| | Trachea | 1 | 2026 | 258 | 0.820 |
Why?
| | Staphylococcus aureus | 2 | 2025 | 459 | 0.810 |
Why?
| | Pneumonia, Bacterial | 1 | 2025 | 115 | 0.790 |
Why?
| | Cross Infection | 4 | 2025 | 261 | 0.790 |
Why?
| | RNA, Viral | 11 | 2020 | 695 | 0.770 |
Why?
| | Coronary Vessels | 3 | 2026 | 246 | 0.770 |
Why?
| | Hospitalization | 15 | 2024 | 2495 | 0.770 |
Why?
| | Antiviral Agents | 6 | 2020 | 776 | 0.760 |
Why?
| | Pneumonia, Mycoplasma | 3 | 2024 | 56 | 0.760 |
Why?
| | Coronaviridae | 2 | 2014 | 4 | 0.750 |
Why?
| | Parechovirus | 3 | 2019 | 8 | 0.730 |
Why?
| | Drug Resistance, Bacterial | 3 | 2022 | 185 | 0.710 |
Why?
| | Immunologic Factors | 2 | 2026 | 261 | 0.700 |
Why?
| | Diagnostic Tests, Routine | 2 | 2019 | 107 | 0.680 |
Why?
| | Nervous System Malformations | 1 | 2022 | 46 | 0.680 |
Why?
| | Respiration, Artificial | 2 | 2026 | 716 | 0.680 |
Why?
| | Virus Cultivation | 2 | 2018 | 31 | 0.660 |
Why?
| | Rhinovirus | 5 | 2017 | 60 | 0.660 |
Why?
| | Enteropathogenic Escherichia coli | 1 | 2020 | 1 | 0.660 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2020 | 6 | 0.660 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 44 | 0.660 |
Why?
| | Acute Disease | 12 | 2025 | 1049 | 0.640 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.630 |
Why?
| | Hospitals | 4 | 2021 | 737 | 0.630 |
Why?
| | Adenoviridae Infections | 2 | 2023 | 20 | 0.620 |
Why?
| | Escherichia coli Infections | 1 | 2020 | 125 | 0.610 |
Why?
| | Acyclovir | 1 | 2020 | 98 | 0.610 |
Why?
| | Serratia Infections | 1 | 2019 | 8 | 0.600 |
Why?
| | Serratia marcescens | 1 | 2019 | 17 | 0.590 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 26 | 0.590 |
Why?
| | Pneumonia | 1 | 2025 | 636 | 0.580 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 36 | 0.580 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 0.580 |
Why?
| | Drug Utilization | 2 | 2017 | 171 | 0.580 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2026 | 251 | 0.580 |
Why?
| | Seasons | 10 | 2023 | 540 | 0.580 |
Why?
| | Receptors, Virus | 3 | 2017 | 95 | 0.580 |
Why?
| | Microbial Sensitivity Tests | 4 | 2026 | 367 | 0.580 |
Why?
| | Equipment Contamination | 1 | 2019 | 67 | 0.580 |
Why?
| | Syringes | 1 | 2019 | 49 | 0.570 |
Why?
| | Neisseriaceae Infections | 1 | 2018 | 6 | 0.570 |
Why?
| | Kingella kingae | 1 | 2018 | 12 | 0.560 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 387 | 0.560 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 51 | 0.560 |
Why?
| | Adenoviridae | 3 | 2023 | 199 | 0.560 |
Why?
| | Steroids | 1 | 2019 | 162 | 0.560 |
Why?
| | Enterovirus A, Human | 1 | 2018 | 13 | 0.560 |
Why?
| | Herpes Simplex | 2 | 2018 | 102 | 0.550 |
Why?
| | Fluoxetine | 1 | 2018 | 57 | 0.540 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 222 | 0.520 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2017 | 27 | 0.520 |
Why?
| | Escherichia coli | 2 | 2025 | 836 | 0.520 |
Why?
| | Staphylococcal Infections | 3 | 2026 | 395 | 0.480 |
Why?
| | Time Factors | 10 | 2021 | 7173 | 0.470 |
Why?
| | Viral Tropism | 2 | 2015 | 37 | 0.470 |
Why?
| | Viruses | 5 | 2022 | 166 | 0.470 |
Why?
| | Osteoarthritis | 1 | 2018 | 204 | 0.470 |
Why?
| | Molecular Epidemiology | 2 | 2017 | 74 | 0.460 |
Why?
| | Phylogeny | 9 | 2016 | 924 | 0.460 |
Why?
| | Mycoplasma pneumoniae | 3 | 2024 | 54 | 0.460 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.460 |
Why?
| | Catheter-Related Infections | 1 | 2016 | 98 | 0.450 |
Why?
| | Case-Control Studies | 9 | 2024 | 3660 | 0.440 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 40 | 0.440 |
Why?
| | Adenovirus Infections, Human | 1 | 2015 | 15 | 0.440 |
Why?
| | Coronary Aneurysm | 3 | 2026 | 17 | 0.440 |
Why?
| | Calcitonin | 1 | 2015 | 27 | 0.440 |
Why?
| | Genome, Viral | 3 | 2016 | 216 | 0.440 |
Why?
| | Caliciviridae Infections | 1 | 2015 | 18 | 0.440 |
Why?
| | Rotavirus Infections | 1 | 2015 | 37 | 0.430 |
Why?
| | Muscle Hypotonia | 1 | 2015 | 34 | 0.430 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 442 | 0.430 |
Why?
| | Cohort Studies | 10 | 2024 | 6095 | 0.430 |
Why?
| | United States | 22 | 2026 | 16313 | 0.430 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 124 | 0.420 |
Why?
| | Prospective Studies | 9 | 2025 | 8165 | 0.420 |
Why?
| | Pneumonia, Pneumococcal | 2 | 2025 | 50 | 0.420 |
Why?
| | Virus Diseases | 2 | 2025 | 218 | 0.420 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.410 |
Why?
| | Coronaviridae Infections | 1 | 2014 | 3 | 0.410 |
Why?
| | Metapneumovirus | 2 | 2025 | 16 | 0.410 |
Why?
| | Motor Neurons | 1 | 2016 | 236 | 0.400 |
Why?
| | Whole Genome Sequencing | 1 | 2015 | 183 | 0.400 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.400 |
Why?
| | Haemophilus Infections | 2 | 2024 | 46 | 0.400 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 148 | 0.390 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 754 | 0.390 |
Why?
| | Prevalence | 7 | 2025 | 2888 | 0.390 |
Why?
| | Fever | 6 | 2022 | 320 | 0.380 |
Why?
| | Neuraminidase | 3 | 2020 | 26 | 0.370 |
Why?
| | Arthritis, Infectious | 2 | 2026 | 77 | 0.370 |
Why?
| | Coronavirus NL63, Human | 1 | 2012 | 3 | 0.370 |
Why?
| | Betacoronavirus | 3 | 2020 | 288 | 0.360 |
Why?
| | Genotype | 4 | 2017 | 1875 | 0.360 |
Why?
| | Metagenomics | 5 | 2021 | 151 | 0.360 |
Why?
| | Sepsis | 1 | 2018 | 671 | 0.350 |
Why?
| | Viral Load | 3 | 2024 | 528 | 0.350 |
Why?
| | Viral Envelope Proteins | 1 | 2012 | 98 | 0.350 |
Why?
| | Treatment Outcome | 11 | 2026 | 11944 | 0.340 |
Why?
| | Recombination, Genetic | 1 | 2012 | 205 | 0.330 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 172 | 0.330 |
Why?
| | Genetic Variation | 2 | 2014 | 995 | 0.320 |
Why?
| | Cluster Analysis | 5 | 2021 | 501 | 0.320 |
Why?
| | Coinfection | 3 | 2022 | 143 | 0.310 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.310 |
Why?
| | Young Adult | 17 | 2024 | 14437 | 0.300 |
Why?
| | Rodentia | 7 | 2010 | 62 | 0.300 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 499 | 0.300 |
Why?
| | Infection Control | 2 | 2025 | 174 | 0.300 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 700 | 0.290 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1219 | 0.280 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2886 | 0.270 |
Why?
| | beta-Lactamases | 2 | 2025 | 54 | 0.270 |
Why?
| | Virus Internalization | 4 | 2017 | 65 | 0.270 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.270 |
Why?
| | Critical Care | 4 | 2021 | 705 | 0.260 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 6003 | 0.260 |
Why?
| | Immunity, Innate | 1 | 2013 | 840 | 0.250 |
Why?
| | Diagnosis, Differential | 7 | 2020 | 1518 | 0.250 |
Why?
| | Neoplasms | 3 | 2023 | 2946 | 0.250 |
Why?
| | Algorithms | 4 | 2025 | 1868 | 0.250 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2974 | 0.250 |
Why?
| | Mycoplasma hominis | 1 | 2006 | 4 | 0.250 |
Why?
| | Gentian Violet | 1 | 2026 | 4 | 0.240 |
Why?
| | Phenazines | 1 | 2026 | 17 | 0.240 |
Why?
| | HIV Infections | 5 | 2017 | 3235 | 0.240 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3445 | 0.230 |
Why?
| | Endocarditis, Bacterial | 1 | 2006 | 47 | 0.230 |
Why?
| | Apolipoproteins E | 4 | 2016 | 96 | 0.230 |
Why?
| | Murine hepatitis virus | 2 | 2016 | 16 | 0.230 |
Why?
| | Immunization | 2 | 2004 | 375 | 0.230 |
Why?
| | Integrons | 1 | 2025 | 3 | 0.230 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 13 | 0.230 |
Why?
| | Visitors to Patients | 1 | 2025 | 17 | 0.220 |
Why?
| | Enzyme Inhibitors | 3 | 2020 | 822 | 0.220 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.210 |
Why?
| | Critical Illness | 2 | 2025 | 907 | 0.210 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 126 | 0.210 |
Why?
| | Masks | 1 | 2025 | 70 | 0.210 |
Why?
| | DNA, Bacterial | 1 | 2026 | 320 | 0.210 |
Why?
| | Methicillin Resistance | 1 | 2004 | 17 | 0.210 |
Why?
| | Cellulitis | 1 | 2004 | 54 | 0.200 |
Why?
| | Guatemala | 1 | 2025 | 347 | 0.200 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.200 |
Why?
| | Haemophilus influenzae type b | 1 | 2003 | 12 | 0.200 |
Why?
| | ROC Curve | 1 | 2026 | 626 | 0.200 |
Why?
| | Haemophilus Vaccines | 1 | 2003 | 29 | 0.200 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.200 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 539 | 0.200 |
Why?
| | Clindamycin | 2 | 2018 | 14 | 0.200 |
Why?
| | Musculoskeletal Diseases | 1 | 2025 | 94 | 0.190 |
Why?
| | Polysaccharides, Bacterial | 1 | 2003 | 69 | 0.190 |
Why?
| | Antigens, Viral | 3 | 2020 | 186 | 0.190 |
Why?
| | Global Health | 2 | 2021 | 406 | 0.190 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 97 | 0.190 |
Why?
| | Risk Factors | 9 | 2021 | 11016 | 0.190 |
Why?
| | American Heart Association | 1 | 2024 | 363 | 0.190 |
Why?
| | Incidence | 4 | 2021 | 2954 | 0.180 |
Why?
| | Hepatitis C | 4 | 2006 | 256 | 0.180 |
Why?
| | Coronavirus 229E, Human | 1 | 2022 | 7 | 0.180 |
Why?
| | Medical Oncology | 2 | 2023 | 344 | 0.180 |
Why?
| | Critical Pathways | 1 | 2024 | 111 | 0.180 |
Why?
| | Disease Management | 3 | 2024 | 654 | 0.180 |
Why?
| | Canada | 3 | 2025 | 435 | 0.180 |
Why?
| | Logistic Models | 2 | 2018 | 2141 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 70 | 0.180 |
Why?
| | Pharyngitis | 1 | 2022 | 28 | 0.180 |
Why?
| | Vomiting | 2 | 2020 | 131 | 0.170 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2020 | 33 | 0.170 |
Why?
| | Antibodies, Viral | 4 | 2025 | 687 | 0.170 |
Why?
| | North America | 2 | 2016 | 307 | 0.170 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 855 | 0.170 |
Why?
| | Abdominal Pain | 2 | 2020 | 149 | 0.170 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.170 |
Why?
| | Brain Diseases | 2 | 2020 | 158 | 0.170 |
Why?
| | Lethargy | 1 | 2020 | 4 | 0.160 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 38 | 0.160 |
Why?
| | Lung | 1 | 2014 | 4141 | 0.160 |
Why?
| | Arbovirus Infections | 1 | 2020 | 20 | 0.160 |
Why?
| | Intestinal Diseases | 1 | 2020 | 43 | 0.160 |
Why?
| | Databases, Factual | 2 | 2025 | 1504 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 4 | 2018 | 3980 | 0.160 |
Why?
| | Meningitis, Viral | 1 | 2020 | 20 | 0.160 |
Why?
| | Peptide Fragments | 3 | 1999 | 698 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 980 | 0.160 |
Why?
| | Animals | 23 | 2022 | 38416 | 0.160 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.160 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 26 | 0.160 |
Why?
| | Medical Records | 2 | 2018 | 191 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2005 | 541 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2021 | 202 | 0.150 |
Why?
| | Myositis | 1 | 2020 | 57 | 0.150 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 50 | 0.150 |
Why?
| | Echocardiography | 3 | 2026 | 652 | 0.150 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.150 |
Why?
| | Consciousness Disorders | 1 | 2019 | 25 | 0.150 |
Why?
| | Amino Acid Sequence | 5 | 2016 | 2134 | 0.150 |
Why?
| | Length of Stay | 3 | 2020 | 1371 | 0.150 |
Why?
| | Hepatitis | 1 | 2019 | 43 | 0.140 |
Why?
| | Receptors, Lipoprotein | 1 | 1999 | 15 | 0.140 |
Why?
| | Epithelial Cells | 3 | 2015 | 1141 | 0.140 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.140 |
Why?
| | Machine Learning | 1 | 2025 | 596 | 0.140 |
Why?
| | Adult | 20 | 2023 | 41404 | 0.140 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5477 | 0.140 |
Why?
| | Abdomen | 1 | 2019 | 142 | 0.140 |
Why?
| | HEK293 Cells | 3 | 2016 | 745 | 0.140 |
Why?
| | Immunoglobulin G | 2 | 2020 | 901 | 0.140 |
Why?
| | Vero Cells | 2 | 2015 | 83 | 0.140 |
Why?
| | Methyltransferases | 1 | 2018 | 75 | 0.130 |
Why?
| | Hepacivirus | 3 | 2017 | 243 | 0.130 |
Why?
| | Body Fluids | 1 | 2018 | 71 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2006 | 941 | 0.130 |
Why?
| | Sequence Alignment | 2 | 2016 | 362 | 0.130 |
Why?
| | Lipoproteins | 1 | 1999 | 166 | 0.130 |
Why?
| | Microscopy, Electron | 4 | 2015 | 417 | 0.130 |
Why?
| | Receptors, Immunologic | 1 | 1999 | 210 | 0.130 |
Why?
| | Chlamydophila pneumoniae | 1 | 2017 | 12 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 249 | 0.130 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.130 |
Why?
| | Mycoplasma Infections | 1 | 2017 | 17 | 0.130 |
Why?
| | Fluorenes | 1 | 2017 | 45 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1845 | 0.130 |
Why?
| | Sofosbuvir | 1 | 2017 | 62 | 0.130 |
Why?
| | Stomach | 1 | 2017 | 111 | 0.130 |
Why?
| | Mouth Mucosa | 1 | 2017 | 85 | 0.130 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 81 | 0.120 |
Why?
| | Prognosis | 2 | 2016 | 4384 | 0.120 |
Why?
| | Densovirus | 1 | 2016 | 3 | 0.120 |
Why?
| | Tristetraprolin | 1 | 2016 | 8 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2015 | 1514 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 109 | 0.120 |
Why?
| | Intensive Care Units | 2 | 2015 | 928 | 0.120 |
Why?
| | Organ Transplantation | 1 | 2020 | 257 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 190 | 0.120 |
Why?
| | Middle East Respiratory Syndrome Coronavirus | 1 | 2016 | 11 | 0.120 |
Why?
| | Encephalomyelitis | 1 | 2016 | 14 | 0.120 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 22 | 0.120 |
Why?
| | Protein Phosphatase 2 | 1 | 2016 | 41 | 0.120 |
Why?
| | Inflammation | 2 | 2018 | 2921 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 2 | 2017 | 506 | 0.120 |
Why?
| | Vaccination | 1 | 2005 | 1443 | 0.120 |
Why?
| | Borderline Personality Disorder | 1 | 2016 | 16 | 0.120 |
Why?
| | Electromyography | 2 | 2017 | 419 | 0.120 |
Why?
| | Gastrostomy | 1 | 2017 | 130 | 0.120 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Still's Disease, Adult-Onset | 1 | 1995 | 5 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 502 | 0.120 |
Why?
| | Stomach Ulcer | 1 | 1995 | 12 | 0.120 |
Why?
| | Syncope | 1 | 2016 | 56 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2014 | 4170 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2017 | 154 | 0.120 |
Why?
| | Dendritic Spines | 1 | 2016 | 70 | 0.120 |
Why?
| | Psychopathology | 1 | 2016 | 55 | 0.110 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 26 | 0.110 |
Why?
| | Bradycardia | 1 | 2016 | 63 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 278 | 0.110 |
Why?
| | Early Diagnosis | 1 | 2016 | 254 | 0.110 |
Why?
| | Lyme Disease | 1 | 2016 | 58 | 0.110 |
Why?
| | Madin Darby Canine Kidney Cells | 1 | 2015 | 17 | 0.110 |
Why?
| | Seizures | 1 | 2020 | 491 | 0.110 |
Why?
| | Cephalosporins | 1 | 2015 | 45 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2023 | 841 | 0.110 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 264 | 0.110 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 22 | 0.110 |
Why?
| | Sapovirus | 1 | 2015 | 1 | 0.110 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 448 | 0.110 |
Why?
| | Rotavirus | 1 | 2015 | 21 | 0.110 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 138 | 0.110 |
Why?
| | Peritonitis | 1 | 1995 | 83 | 0.110 |
Why?
| | Colonoscopy | 1 | 2017 | 267 | 0.110 |
Why?
| | Norovirus | 1 | 2015 | 22 | 0.110 |
Why?
| | Mother-Child Relations | 1 | 2016 | 131 | 0.110 |
Why?
| | Bacterial Proteins | 2 | 2018 | 977 | 0.110 |
Why?
| | Virus Shedding | 1 | 2015 | 53 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1093 | 0.110 |
Why?
| | Health Resources | 1 | 2016 | 133 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 163 | 0.110 |
Why?
| | Bacterial Shedding | 1 | 2014 | 3 | 0.100 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 118 | 0.100 |
Why?
| | Zanamivir | 1 | 2014 | 2 | 0.100 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1046 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1151 | 0.100 |
Why?
| | Rural Population | 1 | 2019 | 685 | 0.100 |
Why?
| | Oseltamivir | 1 | 2014 | 17 | 0.100 |
Why?
| | Cost of Illness | 1 | 2016 | 327 | 0.100 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.100 |
Why?
| | RNA Viruses | 1 | 2015 | 73 | 0.100 |
Why?
| | Republic of Korea | 2 | 2025 | 43 | 0.100 |
Why?
| | Anomie | 1 | 2013 | 3 | 0.100 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.100 |
Why?
| | Giant Cells | 1 | 2013 | 21 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 703 | 0.100 |
Why?
| | Disease Reservoirs | 1 | 2013 | 27 | 0.100 |
Why?
| | Dogs | 1 | 2015 | 518 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 347 | 0.100 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2016 | 459 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 25 | 0.100 |
Why?
| | Particulate Matter | 1 | 2016 | 329 | 0.100 |
Why?
| | Brazil | 1 | 2013 | 179 | 0.100 |
Why?
| | Social Adjustment | 1 | 2013 | 64 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 880 | 0.100 |
Why?
| | Pediatrics | 3 | 2020 | 1139 | 0.090 |
Why?
| | Mexico | 1 | 2013 | 233 | 0.090 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 173 | 0.090 |
Why?
| | Membrane Proteins | 1 | 1999 | 1171 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 324 | 0.090 |
Why?
| | Age Factors | 4 | 2010 | 3370 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2013 | 537 | 0.090 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 41 | 0.090 |
Why?
| | Neuroimaging | 1 | 2014 | 309 | 0.090 |
Why?
| | Middle Aged | 17 | 2020 | 36819 | 0.090 |
Why?
| | Oxygen | 2 | 2023 | 998 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 359 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 638 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 394 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 251 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 583 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 563 | 0.090 |
Why?
| | Biomarkers | 3 | 2021 | 4354 | 0.080 |
Why?
| | Brain | 3 | 2018 | 3009 | 0.080 |
Why?
| | Illinois | 2 | 2015 | 50 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 345 | 0.080 |
Why?
| | Bulbourethral Glands | 1 | 2010 | 1 | 0.080 |
Why?
| | Seminal Vesicles | 1 | 2010 | 9 | 0.080 |
Why?
| | Inpatients | 1 | 2015 | 556 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 105 | 0.080 |
Why?
| | Urogenital System | 1 | 2010 | 16 | 0.080 |
Why?
| | Intestines | 1 | 2013 | 356 | 0.080 |
Why?
| | Peptides | 1 | 2016 | 1003 | 0.080 |
Why?
| | Macrophages, Alveolar | 1 | 2013 | 377 | 0.080 |
Why?
| | Mothers | 1 | 2016 | 774 | 0.070 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 773 | 0.070 |
Why?
| | Aspirin | 1 | 2013 | 406 | 0.070 |
Why?
| | Cell Line | 5 | 2017 | 2832 | 0.070 |
Why?
| | Prostate | 1 | 2010 | 160 | 0.070 |
Why?
| | Receptors, Androgen | 1 | 2010 | 149 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 784 | 0.070 |
Why?
| | Cholesteatoma | 1 | 1988 | 10 | 0.070 |
Why?
| | Ear Diseases | 1 | 1988 | 20 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 2001 | 0.070 |
Why?
| | Mental Health Services | 1 | 2013 | 478 | 0.070 |
Why?
| | Disease Transmission, Infectious | 2 | 2005 | 69 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 307 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1993 | 648 | 0.060 |
Why?
| | Adrenal Medulla | 1 | 2007 | 10 | 0.060 |
Why?
| | Chromaffin Cells | 1 | 2007 | 4 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 1993 | 569 | 0.060 |
Why?
| | Cleft Palate | 1 | 1988 | 91 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2016 | 1174 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 1999 | 119 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2016 | 1183 | 0.060 |
Why?
| | Mice | 8 | 2022 | 18493 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2008 | 182 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1798 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 789 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2006 | 70 | 0.060 |
Why?
| | Patient Admission | 1 | 2008 | 220 | 0.060 |
Why?
| | Odds Ratio | 2 | 2021 | 1083 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1993 | 1166 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 30 | 0.060 |
Why?
| | Photoperiod | 2 | 2010 | 55 | 0.060 |
Why?
| | Immunoassay | 1 | 2006 | 109 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 55 | 0.060 |
Why?
| | Serogroup | 1 | 2025 | 46 | 0.060 |
Why?
| | Sexually Transmitted Diseases, Viral | 1 | 2005 | 11 | 0.060 |
Why?
| | Klebsiella pneumoniae | 1 | 2025 | 48 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2019 | 615 | 0.050 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2025 | 77 | 0.050 |
Why?
| | Chicago | 1 | 2004 | 62 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 487 | 0.050 |
Why?
| | Population Surveillance | 1 | 2008 | 486 | 0.050 |
Why?
| | Homosexuality | 1 | 2004 | 18 | 0.050 |
Why?
| | Aged | 8 | 2020 | 26509 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Models, Molecular | 3 | 2017 | 1606 | 0.050 |
Why?
| | Fibroblasts | 3 | 2016 | 1040 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2175 | 0.050 |
Why?
| | Bacterial Capsules | 1 | 2003 | 33 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2791 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2005 | 234 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2131 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 268 | 0.050 |
Why?
| | Streptococcus | 1 | 2023 | 29 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2023 | 337 | 0.050 |
Why?
| | Risk Assessment | 2 | 2019 | 3784 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 168 | 0.050 |
Why?
| | Respiratory System | 1 | 2023 | 150 | 0.050 |
Why?
| | Immunization Schedule | 1 | 2003 | 186 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 677 | 0.040 |
Why?
| | Heparin Lyase | 2 | 1999 | 5 | 0.040 |
Why?
| | Data Collection | 1 | 2005 | 652 | 0.040 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 25 | 0.040 |
Why?
| | Immunization Programs | 1 | 2003 | 194 | 0.040 |
Why?
| | New Zealand | 1 | 2021 | 56 | 0.040 |
Why?
| | Italy | 1 | 2021 | 118 | 0.040 |
Why?
| | Embryo, Mammalian | 2 | 1999 | 234 | 0.040 |
Why?
| | Schools | 1 | 2004 | 452 | 0.040 |
Why?
| | History, 21st Century | 1 | 2022 | 227 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2021 | 148 | 0.040 |
Why?
| | Sertoli Cells | 1 | 2001 | 28 | 0.040 |
Why?
| | Conserved Sequence | 2 | 1998 | 244 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 28 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 289 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 914 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 90 | 0.040 |
Why?
| | Receptors, LDL | 2 | 1998 | 53 | 0.040 |
Why?
| | Lithium | 1 | 2000 | 40 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 35 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 104 | 0.040 |
Why?
| | Comorbidity | 2 | 2021 | 1672 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 137 | 0.040 |
Why?
| | Anti-Ulcer Agents | 1 | 1999 | 12 | 0.040 |
Why?
| | Macrophages | 2 | 2016 | 1530 | 0.040 |
Why?
| | Adrenal Cortex | 1 | 1999 | 33 | 0.040 |
Why?
| | Testis | 1 | 2000 | 165 | 0.040 |
Why?
| | Sesquiterpenes | 1 | 1999 | 52 | 0.040 |
Why?
| | Chlorates | 1 | 1999 | 4 | 0.040 |
Why?
| | Spermatozoa | 1 | 2000 | 109 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2000 | 149 | 0.040 |
Why?
| | Immunocompetence | 1 | 2019 | 46 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 1999 | 13 | 0.040 |
Why?
| | Scavenger Receptors, Class B | 1 | 1999 | 14 | 0.040 |
Why?
| | Egtazic Acid | 1 | 1999 | 37 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 852 | 0.040 |
Why?
| | Reproduction | 1 | 2001 | 212 | 0.040 |
Why?
| | Receptors, Scavenger | 1 | 1999 | 22 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 59 | 0.040 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.040 |
Why?
| | Infant, Newborn, Diseases | 1 | 2020 | 116 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 44 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 116 | 0.040 |
Why?
| | Seminiferous Epithelium | 1 | 1998 | 1 | 0.040 |
Why?
| | Europe | 1 | 2020 | 426 | 0.040 |
Why?
| | Lactams | 1 | 1998 | 28 | 0.040 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 194 | 0.040 |
Why?
| | Blood | 1 | 1999 | 107 | 0.030 |
Why?
| | Plasma | 1 | 2020 | 224 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2021 | 430 | 0.030 |
Why?
| | Lipoproteins, HDL | 1 | 1999 | 104 | 0.030 |
Why?
| | Drug Resistance | 1 | 2019 | 145 | 0.030 |
Why?
| | Child Health Services | 1 | 2020 | 191 | 0.030 |
Why?
| | Health Personnel | 1 | 2005 | 759 | 0.030 |
Why?
| | Spermatogenesis | 1 | 1998 | 91 | 0.030 |
Why?
| | Evolution, Molecular | 2 | 2016 | 502 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2020 | 337 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2018 | 319 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2020 | 182 | 0.030 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.030 |
Why?
| | Models, Biological | 1 | 2025 | 1772 | 0.030 |
Why?
| | Patient Discharge | 1 | 2025 | 1002 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 170 | 0.030 |
Why?
| | Models, Chemical | 1 | 1999 | 251 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 318 | 0.030 |
Why?
| | Headache | 1 | 2018 | 151 | 0.030 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 47 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2018 | 152 | 0.030 |
Why?
| | Structural Homology, Protein | 1 | 2017 | 22 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 3029 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2017 | 70 | 0.030 |
Why?
| | Contact Tracing | 1 | 2017 | 26 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 2018 | 109 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 417 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
| | RNA | 1 | 2023 | 916 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2017 | 105 | 0.030 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2016 | 7 | 0.030 |
Why?
| | Macrolides | 1 | 2017 | 68 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 204 | 0.030 |
Why?
| | Colon | 1 | 1999 | 310 | 0.030 |
Why?
| | Amino Alcohols | 1 | 2016 | 2 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2018 | 182 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 874 | 0.030 |
Why?
| | Genomics | 1 | 2022 | 839 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 443 | 0.030 |
Why?
| | Paracentesis | 1 | 1996 | 16 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 201 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.030 |
Why?
| | Clinical Competence | 1 | 2005 | 1260 | 0.030 |
Why?
| | Colitis | 1 | 1999 | 282 | 0.030 |
Why?
| | Ascites | 1 | 1996 | 48 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2016 | 83 | 0.030 |
Why?
| | Eosinophilia | 1 | 2018 | 224 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Membrane Fusion | 1 | 2016 | 41 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 96 | 0.030 |
Why?
| | Dextrans | 1 | 1996 | 84 | 0.030 |
Why?
| | Pyramidal Cells | 1 | 2016 | 81 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 507 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 205 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 130 | 0.030 |
Why?
| | Serine | 1 | 2016 | 143 | 0.030 |
Why?
| | Naproxen | 1 | 1995 | 21 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 487 | 0.030 |
Why?
| | Missouri | 1 | 2015 | 67 | 0.030 |
Why?
| | Prednisolone | 1 | 1995 | 67 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 512 | 0.030 |
Why?
| | Facial Expression | 1 | 2016 | 75 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 313 | 0.030 |
Why?
| | Synovial Membrane | 1 | 2016 | 128 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2030 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 568 | 0.030 |
Why?
| | Respiratory Sounds | 1 | 2015 | 103 | 0.030 |
Why?
| | Epitopes | 1 | 2017 | 475 | 0.030 |
Why?
| | Biodiversity | 1 | 2018 | 315 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 382 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 147 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 762 | 0.030 |
Why?
| | Systole | 1 | 2015 | 181 | 0.030 |
Why?
| | Cough | 1 | 2015 | 124 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2016 | 212 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 308 | 0.030 |
Why?
| | Cote d'Ivoire | 1 | 2014 | 9 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 254 | 0.030 |
Why?
| | Vietnam | 1 | 2014 | 27 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 357 | 0.030 |
Why?
| | Liver Cirrhosis | 1 | 1996 | 289 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 287 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 102 | 0.030 |
Why?
| | Protein Binding | 2 | 2017 | 2249 | 0.030 |
Why?
| | Gene Order | 1 | 2013 | 29 | 0.030 |
Why?
| | Liberia | 1 | 2013 | 15 | 0.020 |
Why?
| | Social Control, Formal | 1 | 2013 | 11 | 0.020 |
Why?
| | Cell Membrane | 2 | 2013 | 711 | 0.020 |
Why?
| | Dyspnea | 1 | 2015 | 252 | 0.020 |
Why?
| | Lentivirus | 1 | 2013 | 62 | 0.020 |
Why?
| | Trypsin | 1 | 2013 | 75 | 0.020 |
Why?
| | Depressive Disorder | 1 | 2016 | 379 | 0.020 |
Why?
| | Kidney | 1 | 2021 | 1511 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 444 | 0.020 |
Why?
| | California | 1 | 2015 | 477 | 0.020 |
Why?
| | Anxiety Disorders | 1 | 2016 | 376 | 0.020 |
Why?
| | Mesna | 1 | 1993 | 15 | 0.020 |
Why?
| | Ifosfamide | 1 | 1993 | 39 | 0.020 |
Why?
| | Alopecia | 1 | 1993 | 37 | 0.020 |
Why?
| | Warfare | 1 | 2013 | 100 | 0.020 |
Why?
| | Synapses | 1 | 2016 | 448 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1598 | 0.020 |
Why?
| | Exanthema | 1 | 2013 | 86 | 0.020 |
Why?
| | Endosomes | 1 | 2013 | 140 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1776 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 536 | 0.020 |
Why?
| | Vulnerable Populations | 1 | 2013 | 177 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1721 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 392 | 0.020 |
Why?
| | Pilot Projects | 1 | 2017 | 1912 | 0.020 |
Why?
| | Nausea | 1 | 1992 | 112 | 0.020 |
Why?
| | HIV-1 | 1 | 2017 | 917 | 0.020 |
Why?
| | Antiemetics | 1 | 1992 | 51 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 43 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 86 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 102 | 0.020 |
Why?
| | Pregnancy | 2 | 2020 | 7276 | 0.020 |
Why?
| | Needs Assessment | 1 | 2013 | 409 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1344 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 151 | 0.020 |
Why?
| | Urethra | 1 | 2010 | 56 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2016 | 886 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2416 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 365 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1991 | 124 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3153 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 654 | 0.020 |
Why?
| | Iowa | 1 | 1988 | 31 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2223 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1149 | 0.020 |
Why?
| | Otitis Media with Effusion | 1 | 1988 | 20 | 0.020 |
Why?
| | Rats, Wistar | 2 | 2000 | 450 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1481 | 0.020 |
Why?
| | Cytokines | 1 | 2016 | 2087 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2812 | 0.020 |
Why?
| | Capsid Proteins | 1 | 2008 | 94 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 1188 | 0.020 |
Why?
| | Catecholamines | 1 | 2007 | 88 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1599 | 0.020 |
Why?
| | Hepatitis C Antigens | 1 | 2006 | 1 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2006 | 11 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2013 | 886 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2006 | 200 | 0.010 |
Why?
| | Rats | 3 | 2000 | 5613 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4605 | 0.010 |
Why?
| | Viral Proteins | 1 | 2008 | 353 | 0.010 |
Why?
| | Qualitative Research | 1 | 2013 | 1732 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2006 | 119 | 0.010 |
Why?
| | France | 1 | 2005 | 40 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 6042 | 0.010 |
Why?
| | Sexuality | 1 | 2005 | 32 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 4130 | 0.010 |
Why?
| | Safe Sex | 1 | 2004 | 24 | 0.010 |
Why?
| | Syphilis | 1 | 2004 | 39 | 0.010 |
Why?
| | Asthma | 1 | 2015 | 1805 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1730 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8429 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1197 | 0.010 |
Why?
| | Organelles | 1 | 2001 | 53 | 0.010 |
Why?
| | Cyclophosphamide | 2 | 1992 | 277 | 0.010 |
Why?
| | Cell Count | 1 | 2001 | 321 | 0.010 |
Why?
| | Sperm Motility | 1 | 2000 | 37 | 0.010 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 1999 | 10 | 0.010 |
Why?
| | Zona Fasciculata | 1 | 1999 | 1 | 0.010 |
Why?
| | Colloids | 1 | 2000 | 59 | 0.010 |
Why?
| | Acetic Acid | 1 | 1999 | 16 | 0.010 |
Why?
| | Irritants | 1 | 1999 | 42 | 0.010 |
Why?
| | Doxorubicin | 2 | 1992 | 411 | 0.010 |
Why?
| | Spermatogonia | 1 | 1998 | 16 | 0.010 |
Why?
| | Melatonin | 1 | 2000 | 164 | 0.010 |
Why?
| | Spermatids | 1 | 1998 | 25 | 0.010 |
Why?
| | Organ Size | 1 | 1999 | 465 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1998 | 152 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1998 | 138 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1998 | 372 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1998 | 567 | 0.010 |
Why?
| | Polysaccharide-Lyases | 1 | 1996 | 11 | 0.010 |
Why?
| | Ascitic Fluid | 1 | 1996 | 15 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 185 | 0.010 |
Why?
| | Half-Life | 1 | 1996 | 157 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1996 | 168 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 1998 | 348 | 0.010 |
Why?
| | Body Weight | 1 | 2000 | 971 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1049 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 798 | 0.010 |
Why?
| | Sex Factors | 1 | 2000 | 2133 | 0.010 |
Why?
| | Protein Conformation | 1 | 1996 | 943 | 0.010 |
Why?
| | Binding Sites | 1 | 1996 | 1319 | 0.010 |
Why?
| | Thiethylperazine | 1 | 1992 | 1 | 0.010 |
Why?
| | Amitriptyline | 1 | 1992 | 25 | 0.010 |
Why?
| | Methylprednisolone | 1 | 1992 | 59 | 0.010 |
Why?
| | Procarbazine | 1 | 1991 | 9 | 0.010 |
Why?
| | Fluorouracil | 1 | 1992 | 232 | 0.010 |
Why?
| | Leucovorin | 1 | 1991 | 98 | 0.010 |
Why?
| | Neurons | 1 | 2000 | 1672 | 0.000 |
Why?
| | Etoposide | 1 | 1991 | 169 | 0.000 |
Why?
| | Vincristine | 1 | 1991 | 148 | 0.000 |
Why?
| | Prednisone | 1 | 1991 | 230 | 0.000 |
Why?
| | Methotrexate | 1 | 1991 | 235 | 0.000 |
Why?
| | Liver | 1 | 1996 | 1916 | 0.000 |
Why?
|
|
Dominguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|